2021
DOI: 10.1089/neu.2020.7448
|View full text |Cite
|
Sign up to set email alerts
|

Longitudinal Course of Traumatic Brain Injury Biomarkers for the Prediction of Clinical Outcomes: A Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
17
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(18 citation statements)
references
References 33 publications
0
17
1
Order By: Relevance
“…Of all the patients that required airway support, 31.8% of them were already intubated when they arrived at the Emergency Department. Many studies showed that a risk factor associated with mortality is a need for MV, however, the results of our study did not support this (12). TBI deaths due to cardiac arrest are also very high.…”
Section: Discussioncontrasting
confidence: 99%
“…Of all the patients that required airway support, 31.8% of them were already intubated when they arrived at the Emergency Department. Many studies showed that a risk factor associated with mortality is a need for MV, however, the results of our study did not support this (12). TBI deaths due to cardiac arrest are also very high.…”
Section: Discussioncontrasting
confidence: 99%
“…44,45 It has been shown that GFAP and UCH-L1 can aid in detecting intracranial lesions, predicting unfavorable outcomes, and guiding therapeutic interventions, according to meta-analyses and longitudinal studies. 44,46 Moreover, evaluating multiple biomarkers with distinct cellular origins can improve outcome prediction models, highlighting the importance of incorporating these biomarkers into evaluations of TBI patients. 45 Additionally, numerous studies have proposed cutoff values by illustrating a correlation between elevated GFAP and UCH-L1 levels with TBI diagnosis or prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…It is believed that these biomarkers may be more cost-effective than other diagnostic tests. To date, biofluid-based biomarkers known to have diagnostic and prognostic potential in TBI include S100B, neuron-specific enolase, UCH-L1 (neuronal damage marker), and GFAP (astrocyte damage marker) [ 65 ].…”
Section: Biomarkersmentioning
confidence: 99%